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Antimicrobial resistance to penicillin and macrolides in
Streptococcus pneumoniae has increased in the United States
over the past decade. Considerable geographic variation in
susceptibility necessitates regional resistance tracking. Tradi-
tional active surveillance is labor intensive and costly. We col-
lected antibiogram reports from North Carolina hospitals and
assessed pneumococcal susceptibility to multiple agents from
1996 through 2000. Susceptibility in North Carolina was consis-
tently lower than the national average. Aggregating antibio-
gram data is a feasible and timely method of monitoring
regional susceptibility patterns and may also prove beneficial in
measuring the effects of interventions to decrease antimicrobial
resistance.
treptococcus pneumoniae is a leading cause of commu-
nity-acquired illness, resulting in an estimated 3,000 cases
of meningitis, 50,000 cases of bacteremia, 500,000 cases of
pneumonia, and 7 million cases of otitis media each year in the
United States (1). Even with appropriate antimicrobial therapy,
case-fatality rates for high-risk patients can be as high as 40%
for bacteremia and 55% for meningitis (1). Surveillance sys-
tems have shown decreasing antimicrobial susceptibility
among pneumococci (2–13). A comparison of susceptibility
among combined respiratory and invasive isolates from respi-
ratory seasons 1994–1995 and 1999–2000 showed a decrease
in both penicillin susceptibility (from 76% to 66%) and eryth-
romycin susceptibility (from 90% to 74%) (8). An examina-
tion of only invasive isolates from 1997 and 2000 also showed
a decline in isolates’ susceptibility to penicillin (from 75% to
73%) and to erythromycin (from 85% to 78%) (2,5).
Many of the current surveillance systems monitoring
emerging drug resistance detect susceptibility patterns over
large areas, such as an entire country (2,6,9,13). Results may
not be generalizable to all locations within the study area (1).
For example, although the overall proportion of penicillin-
nonsusceptible pneumococci within a seven-region, popula-
tion-based, active surveillance program was 25%, the propor-
tion ranged from 15% in Maryland to 38% in Tennessee (14).
Data are typically gathered from a limited number of medical
establishments within a specified region; national surveillance
systems may not collect data from every state. Monitoring
trends in pneumococcal susceptibility over smaller geographic
areas is necessary to aid clinicians in choosing the best drug
treatment for empiric therapy (1). This local information can
also help evaluate efforts to decrease resistance rates through
judicious antibiotic use.
Chin et al. compared antimicrobial susceptibility results
from active and antibiogram surveillance of pneumococcal
isolates at 12 hospitals in the Portland, Oregon, area in 1996
(15). Active surveillance was defined as collecting isolates and
patient data from participating hospitals and performing sus-
ceptibility testing at a centralized laboratory (15,16). Antibio-
gram surveillance is quite different. Clinical laboratories
assess the antimicrobial susceptibilities of bacterial isolates
and summarize all susceptibility results for a specified period
on an antibiogram report. Antibiograms conform to the sus-
ceptibility testing practices of individual laboratories, include
information on both sterile and nonsterile isolates, may
include duplicate isolates from a single patient, and lack an
epidemiologic characterization of the patient or isolate. The
data contained on laboratory-specific antibiograms, however,
can be compiled to assess regional susceptibility, monitor
trends over time, and assess effects of interventions designed
to reduce antibiotic resistance through judicious antibiotic use.
Chin et al. found no statistically significant difference in
results obtained by the two methods for any of the four drugs
tested at the 12 Portland area hospitals, except for a single
drug at a single hospital where erythromycin susceptibility
was reported at 97% by active surveillance and 84% from the
antibiogram (chi square p=0.01) (15). The cost difference
between the active and antibiogram surveillance systems was
substantial: $52,000 for active surveillance and $700 for anti-
biogram surveillance. The authors concluded that although
antibiogram surveillance produced less information than
active surveillance, “antibiograms provided accurate, commu-
nity-specific drug-resistant S. pneumoniae data.” 
We examined the practicability of collecting hospital anti-
biogram data in North Carolina, a state with a population of
8,049,313 people and a land area of 48,711 square miles
divided into 100 counties (17). We also assessed pneumococ-
cal susceptibility to multiple antimicrobial agents using the
aggregated antibiogram data.
Methods
This study was conducted in North Carolina from April to
September 2001. A study packet was mailed in April 2001 to
the directors of clinical microbiology laboratories at all 114
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North Carolina hospitals identified by the Centers for Medi-
care and Medicaid Services (CMS). Hospitals subsequently
identifying themselves as specialty hospitals (e.g., psychiatric,
drug treatment) were excluded from all analyses. The packet
included a letter describing the project, a questionnaire on hos-
pital characteristics and laboratory testing methods, a request
for submission of S. pneumoniae antibiogram data for each
year from 1996 to 2000, and a prepaid, preaddressed, return
express mail envelope. The nature of the information provided
on hospital antibiograms does not necessarily allow for identi-
fication of duplicate specimens from the same patient, differ-
entiation of susceptibility results by source of specimen, or
determination of conformance to National Committee for
Clinical Laboratory Standards (NCCLS) guidelines for sus-
ceptibility cut points. 
From the antibiograms, the numbers of pneumococcal iso-
lates tested and numbers of isolates testing susceptible were
added across all hospitals for each antimicrobial agent for each
year of data to create statewide summary totals. Data for drugs
that predictably elicit the same susceptibility result were com-
bined: penicillin/oxacillin, cefotaxime/ceftriaxone, and levof-
loxacin/ofloxacin. Antibiogram data from each hospital for
each year of data were assessed for inclusion. Data from anti-
biograms reporting 1) testing results cumulative over >1 year,
2) percentages of susceptible isolates without providing the
total number of isolates tested, 3) more than one susceptibility
value for the same drug for the same period, or 4) results by
nursing unit or named patient were all excluded for the year
and drug in question. We also excluded data for drugs other
than penicillin if more isolates were tested for penicillin sus-
ceptibility than for the other drugs, and the antibiogram did not
clearly indicate that the subgroup selected for additional test-
ing was based on the source of the specimen (i.e., blood-
stream). Testing only penicillin-nonsusceptible isolates for
susceptibility to other drugs could yield misleading results
because penicillin-resistant isolates are more likely to be resis-
tant to other drugs as well (8). 
The aggregated statewide summary totals were used to cal-
culate yearly susceptibility proportions for nine different anti-
biotics for the entire state. Nonsusceptible isolates
encompassed those identified as either intermediate- or high-
level resistant. Susceptibility proportions for penicillin were
also stratified by geographic region of the state. Hospitals
were categorized into three regions (west, central, east) by the
county the respondent listed on the questionnaire. The Com-
mittee on the Protection of the Rights of Human Subjects, Uni-
versity of North Carolina School of Medicine, granted
Institutional Review Board approval.
North Carolina’s pneumococcal susceptibility pattern from
1997 through 2000 was compared to patterns shown by
national surveillance systems tracking S. pneumoniae suscepti-
bility. Data from published reports were included if they cov-
ered a period of no more than 12 months and identified the
source of isolates as respiratory, invasive, or both. If the sur-
veillance period overlapped two calendar years while covering
one respiratory season, the data were classified by the latter
year. For instance, isolates collected from October 1999
through April 2000 were labeled as year 2000 data.
We used the Cochran-Armitage trend test, which tests for
trends in binomial proportions across levels of an ordinal
covariate, to evaluate temporal patterns in the data. A two-
sided p-value <0.05 was considered statistically significant.
Trend tests were performed by using SAS version 8.1 (SAS
Institute, Inc., Cary, NC). Exact binomial 95% confidence
intervals were calculated for proportions by using Stata ver-
sion 7.0 (Stata Corporation, College Station, TX). 
Results
Overall, 60 of the 110 (55%) potentially eligible hospitals
replied to the survey, although ultimately fewer hospitals were
able to contribute pneumococcal susceptibility data. Thirty of
the 114 CMS-identified hospitals responded to the initial
request for information within the first month. After follow-up
telephone calls to the remaining 84 hospitals, 30 additional
hospitals responded. Four hospitals were excluded: one listed
under two different names, one psychiatric hospital, one ortho-
pedic hospital, and one alcohol treatment center. North Caro-
lina hospitals not enumerated on the CMS list, and hence not
invited to participate in this study, included five military, four
Veterans Affairs, and two prison hospitals, as well as several
long-term care and rehabilitation centers. Additionally, small
hospitals that were part of a health-care system dominated by
one large hospital were frequently omitted from the CMS list.
These noninvited hospitals were primarily rural, community
facilities.
The proportion of responding hospitals was similar across
the three regions of the state: 17/30 (57%) hospitals in the
west, 27/51 (53%) in the central region, and 16/29 (55%) in
the east. The average number of beds was 257 (range 40 to
>1,000). The central region contained most of the state’s large,
academic hospital centers as well as most of its urban counties.
No discernable difference was evident between the 50 poten-
tially eligible hospitals that did not participate and the 60 that
did, except that all major academic centers participated. 
The primary source of pneumococcal isolates was speci-
mens from hospitalized patients in 74% of hospitals and outpa-
tients in 12%. The remaining specimens came from emergency
departments, nursing homes, and physicians’ offices. Among
the hospitals describing susceptibility testing methods, 51%
used E-test, 47% oxacillin screening, 36% MIC broth dilution,
and 20% disk diffusion. Many hospitals performed more than
one type of susceptibility testing. Although 11 hospitals
reported differentiating sterile from nonsterile isolates, only 7
hospitals provided this stratification on their antibiograms.
Eleven of the 60 (18%) hospitals responding to the study
request did not provide antibiogram data. Of these hospitals,
nine did not perform on-site susceptibility testing, and two
gave no explanation for not submitting antibiograms. One
additional hospital reporting off-site testing made antibiogram
information available through a reference laboratory. AlthoughEmerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 213
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49 hospitals contributed antibiogram data for at least one drug
for at least 1 year, not all of the data from these antibiograms
qualified for inclusion in the analyses. Susceptibility data were
excluded for at least one class of drugs for >12 months from
1996 to 2000 for the following reasons: 1) seven antibiograms
provided data for a period of more than 12 months, 2) four
antibiograms reported susceptibility rates without numbers of
isolates tested, 3) one antibiogram listed more than one sus-
ceptibility result for the same drug for the same period, 4) two
antibiograms provided results by nursing unit or named
patient, and 5) 12 antibiograms reported more isolates tested
for penicillin susceptibility than for susceptibility to other
drugs without explaining the drop-off in isolate number, there-
fore, requiring exclusion of the nonpenicillin data. After
accounting for the aforementioned exclusions, the number of
antibiograms with usable data for any single drug for a given
1-year period ranged from 1 (levofloxacin, 1996 and 1997) to
42 (penicillin, 2000).
Although most hospitals submitted susceptibility testing
results for 2000, fewer did so for earlier years. The numbers of
hospitals providing data on penicillin susceptibility were 18
hospitals (1,854 isolates) for 1996, 24 hospitals (2,406 iso-
lates) for 1997, 33 hospitals (2,827 isolates) for 1998, 36 hos-
pitals (3,562 isolates) for 1999, and 42 hospitals (3,497
isolates) for 2000 (Table 1). The numbers of hospitals submit-
ting data on macrolide susceptibility also increased over the
years: four hospitals (488 isolates) for 1996, 11 hospitals (786
isolates) for 1997, 17 hospitals (1,095 isolates) for 1998, 20
hospitals (1,397 isolates) for 1999, and 27 hospitals (1,762 iso-
lates) for 2000 (Table 1).
From 1996 to 2000, the proportion of S. pneumoniae iso-
lates testing susceptible to penicillin decreased (p<0.001) (Fig-
ure 1). Although 65% of isolates were reported as susceptible
to penicillin in 1996, only 52% were susceptible in 2000
(p<0.001). This pattern of decreasing susceptibility was also
evident when stratifying by region of the state (p<0.001 for
each region) (Figure 2). From 1997 on, no statistically signifi-
cant difference in susceptibility was found between either the
west and eastern regions or the west and central regions. How-
ever, penicillin susceptibility was significantly lower (10%) in
the east than in the central region during this time period. 
A subanalysis of the 15 hospitals for which usable infor-
mation on penicillin susceptibility was available for each year
produced a comparable trend. Although with this reduced
amount of data susceptibility was higher in 1996 (69%) than in
the full analysis (65%) (chi square p=0.03), the trend over time
remained consistent (p<0.001). By 2000, 54% of the isolates
reported at these 15 hospitals were susceptible to penicillin,
compared to 52% in the entire study group (chi-square
p=0.13). 
Among penicillin-nonsusceptible isolates, the proportions
intermediate and resistant were available from 5 hospitals (419
isolates) in 1996, 6 hospitals (592 isolates) in 1997, 11 hospi-
tals (849 isolates) in 1998, 12 hospitals (1,184 isolates) in
1999, and 11 hospitals (1,055 isolates) in 2000. These repre-
sented between one-quarter and one-third of all isolates tested
for penicillin susceptibility, depending on the year. During the
5-year period, the proportion of susceptible isolates appeared
to decrease, the proportion of resistant isolates increased, and
the proportion of intermediate isolates showed little change
(Figure 3). 
Macrolide susceptibility decreased from 78% in 1996 to
61% in 2000 (p<0.001). From 1996 to 2000, the proportion of
S. pneumoniae isolates susceptible to cefotaxime decreased
8%. Although third-generation cephalosporins did not show a
consistent decrease in susceptibility each year, the decline dur-
ing the 5-year period was still significant (p<0.001). Suscepti-
bility to quinolones and vancomycin remained high, despite
the fact that two hospitals, one for two different years, reported
a total of five isolates as vancomycin-resistant. The low level
of levofloxacin susceptibility in 1998 (92%) was based on
only 237 isolates. Larger numbers of isolates available in sub-
Table 1. Streptococcus pneumoniae susceptibility to nine antimicrobial agents, North Carolina, 1996–2000
Year
% of all isolates susceptible toa
Penicillin Erythromycin Cefotaxime Levofloxacin Tmp-smxb Tetracycline Clindamycin Vancomycin Chloramphenicol
1996 65 (18; 1,854) 78 (4; 488) 85(9; 985) 100 (1; 205) 64 (5; 626) 96 (2; 254) 90(4; 492) 100 (7; 580) 93 (2; 381)
1997 63 (24; 2,406) 69 (11; 786) 80 (13; 1,272) 100 (1; 283) 57 (11; 786) 79 (4; 66) 76 (7; 655) 100 (11; 903) 95 (3; 117)
1998 56 (33; 2,827) 64 (17; 1,095) 83 (20; 1,970) 92 (4; 237) 51 (16; 975) 83 (10; 402) 88 (11; 606) 100 (19; 1,202) 89 (10; 520)
1999 54 (36; 3,562) 61 (20; 1,397) 80 (22; 2,062) 94 (5; 525) 51 (16; 1,068) 84 (10; 406) 85 (13; 1,017) 100 (21; 1,308) 92 (9; 540)
2000 52 (42; 3,497) 61 (27; 1,762) 77 (27; 2,296) 98 (12; 822) 50 (20; 1,292) 81 (14; 717) 88 (18; 1,238) 100 (26; 1,648) 94 (12; 730)
aValues in parentheses are number of hospitals contributing data and total number of isolates reported, respectively.
bTmp-smx, trimethoprim-sulfamethoxazole.
Figure 1. Streptococcus pneumoniae penicillin susceptibility, North
Carolina, 1996–2000. Error bars represent 95% confidence intervals.RESEARCH
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sequent years did not support a pattern of greatly reduced sus-
ceptibility.
Discussion
Aggregating hospital antibiogram data from the state of
North Carolina appears to be a feasible, practical method for
monitoring trends in pneumococcal susceptibility. Large num-
bers of isolates are available for annual comparisons with con-
sistent reporting on penicillin, albeit less consistent reporting
on other drugs. Susceptibility to clinically important antibiot-
ics was shown to decrease significantly. 
The observed progression of both penicillin and macrolide
resistance is of particular concern. The increase in penicillin
resistance appears to correlate with an increase in high-level
rather than intermediate-level resistance and high-level peni-
cillin resistance has been associated with worse outcomes for
pneumococcal infections (18). The increased macrolide resis-
tance is most likely mediated by a low-level efflux pump since
clindamycin susceptibility remained stable over the study
period (19). Erythromycin susceptibility generally predicts
that of azithromycin and clarithromycin (20). Increased mac-
rolide resistance is disturbing since erythromycin, azithromy-
cin, and clarithromycin are some of the most commonly
prescribed antibiotics for outpatient treatment of community-
acquired pneumonia and low-level macrolide resistance has
been associated with clinical failure (21–23).
Pneumococcal resistance rates tend to increase moving
along the spectrum of isolates obtained from bloodstream to
lower respiratory tract to upper respiratory tract (8). This fact
potentially confounds point comparisons of resistance rates
since a marked increase in resistance can result from testing a
preponderance of upper respiratory isolates, rather than
reflecting a true increase in the burden of resistant pneumo-
cocci. We were unable to assess the extent to which the source
of the specimen may have produced spurious results since only
seven hospitals identified the specimen source on their antibio-
grams. If the relative distribution of isolates remained the
same, however, the trend would not be altered.
Although Chin et al. showed that antibiogram surveillance
and active surveillance yield comparable results, national data
may not be directly comparable to our findings (15). The
national data used for comparison to this study result from
active surveillance use different reporting periods, and in some
cases focus solely on invasive isolates that have consistently
higher susceptibility than respiratory isolates (8). Pneumococ-
cal susceptibility in North Carolina is nonetheless lower than
reported national averages and appears to be decreasing more
quickly (Table 2). This finding is consistent with compara-
tively low antibiotic susceptibilities previously described for
the Southeast. Active surveillance for year 2000 susceptibility
in the southeastern United States ranged from 56% to 57% for
penicillin and from 61% to 67% for erythromycin (8,12,13).
Antibiogram surveillance is cost efficient. Expenses for
collecting and analyzing five years worth of data from an
entire state were limited to mailings and paper materials
(<$1,000) and the support of one graduate student. Chin et al.
spent $52,000 for 1 year of active surveillance in 12 hospitals.
The antibiogram surveillance had several potential limitations,
however. First, a 55% response rate may be adequate for cer-
tain surveys, but full participation from all N.C. microbiology
laboratories would be the best way to ensure that surveillance
data accurately reflect susceptibility patterns. Furthermore, all
participating hospitals did not submit an antibiogram for each
year nor did all data on each antibiogram meet inclusion crite-
ria. Yet our data included many more hospitals in this study
locale than any previously published surveillance system. Sec-
ond, many hospitals were unable to access data from past
years for a variety of reasons, including changes in testing and
computer systems. Collecting antibiogram reports on a yearly
basis should allow more hospitals to more easily contribute
their data. Third, specimens are increasingly sent to referral
hospitals or reference laboratories. For instance, 9 of the 60
participating hospitals did not have antibiogram data, and we
were able to get results from a reference laboratory for only a
single hospital. The lack of availability of antibiograms at hos-
pitals that use reference laboratories is disconcerting since
information needed to guide local antibiotic decisions is not
accessible. Lastly, testing and reporting procedures were
inconsistent, such as drugs tested, identification of specimen
source, breakdown of intermediate and high-level resistance,
and period covered by the antibiogram. We hope that provid-
ing N.C. microbiology laboratories with these study findings
Figure 2. Streptococcus pneumoniae penicillin susceptibility by geo-
graphic region, North Carolina, 1996–2000. Error bars represent 95%
confidence intervals.
Figure 3. Streptococcus pneumoniae penicillin susceptibility among
isolates differentiating nonsusceptibility levels, North Carolina, 1996–
2000.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 215
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will encourage participation in continued surveillance activi-
ties as well as more uniform testing and reporting procedures. 
The submitted data appeared to be consistent despite the
fact that the population under study changed from year to year
as more data became available. The sub-analysis, reflecting
solely those hospitals providing information for each year
from 1996 to 2000 yielded results comparable to those found
in the overall study. Additionally, the observed susceptibility
results generally support known resistance patterns, such as
the correlation of penicillin and ceftriaxone susceptibility,
lower levels of macrolide than clindamycin susceptibility, and
near universal vancomycin susceptibility (24). 
Combining hospital antibiogram data appears to be an
effective method of tracking antimicrobial susceptibility
among Streptococcus pneumoniae, both in North Carolina and
within regions of the state. To further develop this antibiogram
surveillance system, we are partnering with the North Carolina
State Laboratory of Public Health to establish an electronic
network of microbiology laboratories to enhance interlabora-
tory communication. We hope to share practices, encourage
testing consistent with current NCCLS guidelines, and support
standardized, efficient, annual, electronic submission of anti-
biograms. We also hope that knowledge of N.C. resistance pat-
terns will both guide treatment decisions and motivate
judicious antibiotic prescribing behavior.
Judicious use of antibiotics is essential for their continued
effectiveness. Not only have regional trends in antibiotic resis-
tance been linked to antibiotic use (25–29), but decreasing
antibiotic use has resulted in declining levels of resistance
(30). After an aggressive campaign to educate its population
on the need for shrewd use of antibiotics, the rate of penicillin-
resistant pneumococci in Iceland declined from nearly 20% in
1993 to 16.9% in 1994 (31,32). Regional surveillance can
identify areas most in need of interventions aimed at decreas-
ing resistance and can monitor the progress of these interven-
tions. Aggregating antibiogram data appears to be an easy,
inexpensive, effective way of accomplishing these goals.
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